^
Association details:
| Biomarker: | TERT C228T + FGFR3 amplification + FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma
Published date:
09/19/2020
Excerpt:
The results showed the TERT p.C228T mutation (mutation allele frequency [MAF] = 40%, formalin‐fixed, paraffin‐embedded [FFPE] sample), FGFR3 amplification (copy number [N] = 3.13, FFPE sample), and an FGFR3‐TACC3 fusion...The patient was administered anlotinib 12 mg p.o. every day (days 1–14, 21‐day cycle) (anlotinib clinical study NCT04004975) and oral TMZ chemotherapy 100 mg/m2 (days 1–7, days 15–21, 28‐day cycle; 12 cycles). After 2 months of therapy, the patient achieved a partial response that has been maintained for >17 months of follow‐up.
DOI:
10.1002/onco.13530
